Mrs. Feryal Dabbagh-Gorjani – Tumor Immunology – Best Researcher Award

Mrs. Feryal Dabbagh-Gorjani - Tumor Immunology - Best Researcher Award

Foroogh Salamat - Iran

Author Profile

Orcid

EARLY ACADEMIC PURSUITS

Feryal Dabbagh Gorjani embarked on her academic journey with a strong foundation in the medical sciences. She pursued a B.Sc in Clinical Laboratory from 2008 to 2010 at the Preclinical School of Iran University of Medical Science, Tehran, Iran. Prior to that, she obtained an associated degree in Clinical Laboratory from the Preclinical School of Islamic Azad University, Tehran Medical Sciences Branch, from 2005 to 2007. Her educational journey culminated in an M.Sc in Medical Immunology from 2011 to 2014 at the Medical School of Shiraz University of Medical Science, Shiraz, Iran.

PROFESSIONAL ENDEAVORS

From December 2023 onwards, Feryal Dabbagh Gorjani has been engaged as a medical advisor at Forough Salamat Mehregan, the official representative of the American company Fairhaven Health. Her role in this capacity involves providing expertise and guidance in medical matters, presumably within the realm of immunology and clinical laboratory science.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Throughout her academic and professional journey, Feryal Dabbagh Gorjani has likely contributed to the field of medical immunology and clinical laboratory science. And her Specific research focuses on immunological diagnostics, disease pathogenesis, and therapeutic interventions.

IMPACT AND INFLUENCE

Her work as a medical advisor suggests that she plays a crucial role in shaping decisions related to health and wellness. Her expertise in medical immunology and clinical laboratory science likely contributes to advancements in diagnostic accuracy, treatment efficacy, and patient care.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Feryal Dabbagh Gorjani's legacy and future contributions lie in her ongoing work as a medical advisor and her potential for further advancements in the fields of medical immunology and clinical laboratory science. As she continues to apply her expertise and knowledge in healthcare settings, her contributions are likely to impact patient outcomes, research advancements, and the broader medical community. Future endeavors may include continued research, publications, and collaborative efforts to address emerging challenges in immunological diagnostics and therapeutics.

Notable Publications

A Comprehensive Review on the Role of Interleukin-40 as a Biomarker for Diagnosing Inflammatory Diseases. 2024

COVID-19 and neurological complications. 2022

EcoImmunology: Evaluative Aspects and Future Perspectives. 2018

Investigating the Association of IL-17A and IL-17F with Susceptibility to Preeclampsia in Iranian Women. 2015

Differences in the expression of TLRs and inflammatory cytokines in preeclamptic compared with healthy pregnant women. 2014

 

 

 

 

Assoc Prof Dr. Mario I. Vega – Tumor Immunology – Best Researcher Award

 

Assoc Prof Dr. Mario I. Vega - Tumor Immunology - Best Researcher Award

University of California Los Angeles - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS:

Mario I. Vega initiated his academic journey at the Universidad AutĆ³noma Metropolitana Campus Xochimilco, Mexico City, serving as a Research Technical Assistant in the Department of Leptospirosis Human Research from 1991 to 1992. He continued his research roles at the Hospital Infantil de Mexico "Federico Gomez" and the Instituto Mexicano del Seguro Social (IMSS) with a focus on immunology and infectious diseases.

PROFESSIONAL ENDEAVORS:

Mario I. Vega's professional trajectory includes positions at prestigious institutions, such as UCLA AIDS Institute and IMSS, where he advanced from Assistant Researcher to Professor in the field of tumor immunology and infectious diseases. Notably, he has been associated with UCLA Medical Center, Jonsson Comprehensive Cancer Center, contributing as Staff Associate Researcher in the Clinical Nutrition Division.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY:

Dr. Vega's research contributions span diverse areas, from rituximab inhibition of p38 MAPK activity in B NHL to extensive work in immunology, cancer, and infectious diseases. His research expertise includes molecular biology, DNA replication, PCR, and immunotherapy. Serving on various review committees and editorial boards, he has actively contributed to scientific evaluations and publications.

IMPACT AND INFLUENCE:

Dr. Mario I. Vega's impact is evident through numerous honors and awards, such as the American Society of Hematology (ASH) Travel Award in 2004 and consecutive Fogarty fellowships at UCLA from 2004 to 2013. His recognition extends to national and international awards in pediatric research, biomedical research, and contributions to scientific journals.

ACADEMIC CITES:

Dr. Vega has left a mark on academia with memberships in esteemed organizations like ASH, AACR, and AAI. His participation in teaching activities, including courses on molecular biology, immunology, and cancer, demonstrates his commitment to knowledge dissemination.

LEGACY AND FUTURE CONTRIBUTIONS:

This overview highlights Dr. Mario I. Vega's academic and professional journey, his substantial contributions to medical research, and the potential impact of his continued work on the fields of immunology and oncology.

Notable Publications

Regulation of KrĆ¼ppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma.2019Ā 

Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.2022

Roles and Regulation of BCL-xL in Hematological Malignancies.2022